The Medicines and Healthcare products Regulatory Agency (MHRA) has given its approval for the first oral GLP-1 receptor agonist tablet, Wegovy (semaglutide), for weight loss and weight management in the UK. This decision marks a significant step forward in offering a new treatment pathway for adults living with obesity or who are overweight with at least one weight-related comorbidity. The tablet formulation presents an alternative to the currently available injectable GLP-1 receptor agonists, which have seen increasing demand.
Experts have welcomed the approval, highlighting the potential for oral formulations to be more appealing to patients. Dr Simon Cork, Senior Lecturer in Physiology at Anglia Ruskin University, noted that oral weight loss drugs represent the 'next generation' of anti-obesity medications. While clinical trials suggest slightly lower levels of weight loss compared to some injectable forms, particularly Mounjaro, the convenience of a tablet could enhance patient adherence and overall access to treatment. Professor Naveed Sattar from the University of Glasgow also emphasised that having more medication options that yield significant weight loss is crucial in tackling the ongoing challenge of obesity.
Clinical evidence supporting the approval includes a large Phase 3 trial programme. One study involving oral semaglutide 25 mg demonstrated an average body weight loss of 13.6% over 64 weeks, significantly higher than the 2.2% observed in the placebo group. This level of efficacy is comparable to that seen with injectable formulations. However, Dr Cork cautioned that real-world results can sometimes differ from those achieved in controlled clinical trials, and the long-term effectiveness outside of these conditions remains to be seen.
Despite the benefits, the practicalities and potential side effects associated with the medication need careful consideration. Dr Marie Spreckley from the University of Cambridge highlighted that while an oral formulation might be more acceptable for some, it still requires strict adherence to dosing instructions. The tablet must be taken under fasting conditions, with patients needing to wait before eating or drinking, which could pose daily challenges. Common adverse events include gastrointestinal issues such as nausea, diarrhoea, constipation, and vomiting, mirroring those seen with other GLP-1 receptor agonists.
The cost implications are also an important factor. Dr Cork suggested that oral Wegovy might be cheaper to manufacture than its injectable counterpart due to not requiring complex pen systems. However, as the active ingredient is still a small peptide, it remains somewhat expensive to produce. The future may see even more cost-effective options, such as Orforglipron, a recently FDA-approved oral GLP-1 receptor agonist with a small molecule active ingredient, which is generally cheaper to manufacture and could retail for less.
Before oral Wegovy becomes widely available on the NHS, it must undergo further regulatory procedures, including assessment by the National Institute for Health and Care Excellence (NICE) to determine its cost-effectiveness and suitability for NHS prescribing. This process will dictate how and when UK patients can access this new treatment option.
Source: Science Media Centre